A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. A phase Ⅰ and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies[J].Journal...
CPT-11 was given as a 90-minute intravenous infusion in repeated 6-week (42-day) courses comprising weekly treatment for 4 consecutive weeks followed by a 2-week rest. Tumor measurements were obtained after every second course of therapy. Toxicity was assessed weekly using the National Cancer ...
Patients and Methods: Twenty-seven previously untreated patients with stage IIIB or IV NSCLC were assessable for toxicity, and 26 were assessable for response. The initial dose of CPT-11 was 30 mg/m2 given as a 90-minute intravenous (IV) infusion on days 1, 8, and 15 in combination ...
A total of 60 patients with chemotherapy-na¨ıve ED-SCLC have been enrolled in the study, and the eligibility criteria included age p70 years, PS 0-2, and no prior therapy. Arm A consisted of P (25 mg mÀ2 day 1) weekly for 9 weeks, CPT-11 (90 day 1) in weeks 1, 3, 5...
CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal canc... L Saltz,Y Shimada,D Khayat - 《Euro...
We report three successful cases with irinotecan (CPT-11 60 mg/m2) + cisplatin (CDDP 30mg/m2) chemotherapy (once in 2 weeks) where S-1 failed to respond to recurrent gastric cancer. Case 1: A total gastrectomy and splenectomy were performed for a cardiac gastric cancer (T3, N2, H0, ...
glycolysis in T cells. We also assessed CPT-11 efficacy in treating autoimmune diseases in models of experimental autoimmune encephalomyelitis and psoriasis. Finally, we proved that treatment of autoimmune diseases with CPT-11 did not suppress long-term immune surveillance for cancer. Taken together, ...
Exclusion criteria were previous exposure to an anti-EGFR therapy or irinotecan-based chemotherapy, previous chemotherapy for metastatic colorectal cancer, adjuvant treatment that was terminated 6 months or less before the start of treatment in our trial, and the use of radiotherapy, surgery (excluding...
中国协和医科大学硕士研究生论文2003年5月主要缩略语表中文名称高效液相.质谱联用高效液相色谱法电喷雾电离源选择离子监测质荷比原子质量单位标准差变异系数总离子流锥孔固相提取药时曲线下面积结直肠癌伊立替康氟屎嘧啶甲酰四氢叶酸草酸铂7.乙基.10羟基喜树碱7.乙基.10羟基喜树碱葡萄糖醛酸甙Karnofsky一般身体状况评分...
intheelinical in and trialsconducted is forthe EuropeJapan.Irinotecan currently approved ofmatastatic eolorectalcancer management in whosediseasehas patients aftertreatment recurredor withfluorouracil—based progressed therapy. aim to The ofthis Was the study investigate pharmacokinetics, ofCPT一11 in...